# Cannabis Shares Retreat After Initial Rally on US Rescheduling > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-shares-market-impact-us-rescheduling/ > **Published:** 2026-04-24T11:05:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:03:35-04:00 > **Clinical Summary:** Explore the cannabis shares market impact following the US federal rescheduling from Schedule I to Schedule III and its implications for investors. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)RegulationResearchHealthcare Access Why This Matters Cannabis rescheduling from Schedule I to Schedule III represents the most significant federal policy shift in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) history, potentially expanding research opportunities and clinical access. The market’s mixed response reflects uncertainty about implementation timelines and practical impacts on [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/) and prescribing practices. Clinical Summary The DEA’s reclassification of cannabis from Schedule I to Schedule III acknowledges accepted medical use while maintaining controlled substance status. This change enables expanded research, potential insurance coverage considerations, and reduced regulatory barriers for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs. However, the rescheduling does not immediately change state-level medical cannabis laws or federal prescribing restrictions, as cannabis remains federally controlled and cannot be prescribed under current physician licensing. Dr. Caplan’s Take “This is a watershed moment for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), but clinicians shouldn’t expect immediate practice changes. The real impact will unfold over months to years as research accelerates and regulatory frameworks adapt to this new classification.” Clinical Perspective 🧠 Clinicians should prepare for increased patient questions about cannabis access and legitimacy while understanding that current state medical cannabis programs remain the primary legal pathway for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/). Watch for evolving insurance policies, expanded research opportunities, and gradual federal-state regulatory alignment over the coming years. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20shares%20retreat%20after%20initial%20rally%20on%20narrow%20scope%20of%20US%20rescheduling%20-...%20%40drcaplan&url=https%3A//wkzo.com/2026/04/23/pot-firms-rally-after-us-reclassifies-marijuana-as-less-dangerous-drug/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//wkzo.com/2026/04/23/pot-firms-rally-after-us-reclassifies-marijuana-as-less-dangerous-drug/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20shares%20retreat%20after%20initial%20rally%20on%20narrow%20scope%20of%20US%20rescheduling%20-...%20--%20via%20%40drcaplan.bsky.social%20https%3A//wkzo.com/2026/04/23/pot-firms-rally-after-us-reclassifies-marijuana-as-less-dangerous-drug/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://wkzo.com/2026/04/23/pot-firms-rally-after-us-reclassifies-marijuana-as-less-dangerous-drug/](https://wkzo.com/2026/04/23/pot-firms-rally-after-us-reclassifies-marijuana-as-less-dangerous-drug/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Administration Moves to Reclassify Marijuana as Schedule III Drug | National News](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) Learn about the Trump administration's historic move to reclassify marijuana as a Schedule III drug and its implications for the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). [Read More](https://cedclinic.com/trump-administration-cannabis-scheduling-changes/) [Some medical marijuana to be reclassified: Will that make cannabis legal nationwide?](https://cedclinic.com/federal-medical-marijuana-reclassification-clinical-implications/) Explore the potential nationwide legal effects of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) reclassification and what it means for patients and investors. [Explore Now](https://cedclinic.com/federal-medical-marijuana-reclassification-clinical-implications/) [State-licensed medical marijuana reclassified to Schedule III drug. What it means for Kentucky – AOL](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) Understand the impact of Schedule III reclassification on state-licensed [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) programs, focusing on Kentucky's evolving landscape. [Learn More](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).